Skip to main content

Search
Profile

Julia Emerson, MD, MPH

|

Overview

Research Focus Area

Translational Research

Publications

Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort.
Pediatric pulmonology , 2010 Sep: 934-44
Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.
Pediatric pulmonology , 2010 Apr: 363-70
Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
Pediatric pulmonology , 2010 Feb: 127-34
Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis.
The Journal of pediatrics , 2009 Nov: 634-9.e1-4
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Contemporary clinical trials , 2009 May: 256-68
Pseudomonas aeruginosa Type III secretion system interacts with phagocytes to modulate systemic infection of zebrafish embryos.
Cellular microbiology , 2009 Feb 6
Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.
The Journal of pediatrics , 2009 Feb: 183-8
Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2009 Jan: 66-70
Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis.
The Journal of infectious diseases , 2007 Oct 1: 1088-92
Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study.
Chest , 2007 Oct: 1212-8
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
Pediatric pulmonology , 2007 Jul: 610-23
Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa.
Proceedings of the National Academy of Sciences of the United States of America , 2006 Dec 26: 19890-5
Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.
Human gene therapy , 2006 Apr: 440-7
Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection.
The Journal of antimicrobial chemotherapy , 2005 Nov: 879-86
Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
Journal of clinical microbiology , 2004 May: 1915-22
Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials.
Pediatric pulmonology , 2004 May: 385-92
Use of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis.
Journal of clinical microbiology , 2003 Sep: 4312-7
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
American journal of respiratory and critical care medicine , 2003 Mar 15: 841-9
Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis.
Chest , 2003 Mar: 792-9
Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.
American journal of respiratory and critical care medicine , 2002 Dec 15: 1550-5
Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.
Pediatric pulmonology , 2002 Aug: 91-100

Find a Doctor or Researcher

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

More search options